A CRA expert provided an opinion on the reasonable royalty due to the exclusive licensee of a patent covering an injectable drug as a result of infringement by a direct competitor. CRA started from the terms of the existing license agreement covering the patent rights, and adjusted these to reflect relevant commercial considerations, including the competitive relationship between the parties, the respective levels of risk borne, and other intellectual property covered by the license.
Trade Secret Litigation Watch: August 2025
In this Insights, CRA’s Intellectual Property Practice consultants take a closer look at trade secret case filings and developments from the first half of...